8-K: Theravance Biopharma: Ampreloxetine Phase 3 Study Misses Primary Endpoint

Theravance Biopharma announced that its Phase 3 CYPRESS Study for ampreloxetine in symptomatic neurogenic orthostatic hypotension did not meet its primary endpoint, but is engaging with the FDA on potential next steps.

Summary

• Theravance Biopharma's Phase 3 CYPRESS Study (0197) for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy (MSA) did not achieve statistical significance on its primary endpoint.
• The primary endpoint measured the change in the OHSA composite score at week 8 during the randomized withdrawal period.
• Secondary endpoints at week 8 also showed similar trends.
• The study did confirm a consistent pressor effect and reaffirmed ampreloxetine's biological activity through changes in blood pressure, heart rate, and norepinephrine levels.
• Ampreloxetine was generally well-tolerated, with safety findings consistent with prior studies, and no signal of worsening supine hypertension.
• The company has conducted post hoc analyses of the CYPRESS dataset and Phase 3 program, which suggest a potential pharmacologic and clinically meaningful treatment effect in a more focused patient population.
• Theravance Biopharma held a Type B meeting with the FDA in May 2026, where the agency indicated the current data package would not support approval but suggested an additional pivotal trial could be a path forward.
• A follow-up Type C meeting with the FDA was requested in July 2026 to discuss the design of a future study.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the primary endpoint miss, though the company is pursuing further discussions with the FDA.

Positives

• Confirmed a consistent pressor effect and reaffirmed ampreloxetine's biological activity.
• Ampreloxetine was generally well-tolerated with safety findings consistent with prior studies, including no signal of worsening supine hypertension.
• Post hoc analyses suggest a potential pharmacologic and clinically meaningful treatment effect in a more focused patient population.
• The FDA has granted a request for a Type C meeting to obtain feedback on a future study design.

Negatives

• The primary endpoint of the Phase 3 CYPRESS Study (0197) was not statistically significant.
• Similar trends were observed in the secondary endpoints at week 8.
• The FDA indicated in May 2026 that the existing clinical data package would not support approval on the current data.

Risks

• Post hoc and exploratory analyses may not be replicated or predict clinical benefit.
• The FDA may reject a proposed study design or require additional trials or data.
• Any additional pivotal trial may be delayed, unsuccessful, or insufficient to support approval.
• Resources or third-party interest needed to develop, partner, license, or otherwise monetize ampreloxetine may not be available.
• No marketing application may be submitted or approved for ampreloxetine.
• The proposed transaction with Zymeworks Inc. may be delayed or not obtained.
• Potential litigation relating to the proposed transaction could be instituted.
• Various conditions to the consummation of the proposed transaction may not be satisfied or waived.

Future Outlook

The company is seeking feedback from the FDA on a future study design for ampreloxetine, suggesting a potential path forward for regulatory approval, subject to further clinical development and data.

Management Comments

• The primary endpoint, the change in OHSA composite score at week 8 during the double-blind randomized withdrawal period, was not statistically significant.
• Similar trends were observed in the secondary endpoints at week 8.
• Changes in blood pressure, heart rate and norepinephrine levels confirmed a consistent pressor effect and reaffirmed ampreloxetine's biological activity.
• Ampreloxetine was generally well tolerated, with safety findings consistent with prior studies, including no signal of worsening of supine hypertension.
• Analysis of the overall dataset provided additional lines of evidence supporting a potential pharmacologic and clinically meaningful treatment effect of ampreloxetine.
• The FDA has granted request for Type C meeting to obtain feedback on a future study design.

Industry Context

StockSavvy.ai notes that the failure to meet primary endpoints in Phase 3 trials is a significant setback in drug development, particularly for rare diseases like nOH. However, the company's proactive engagement with the FDA for a potential future study indicates a continued commitment to ampreloxetine's development, a strategy often seen when companies believe in the drug's underlying efficacy despite initial trial results.

Legal Proceedings

• Potential litigation relating to the proposed transaction between the Company and Zymeworks Inc. that could be instituted against the Company or its directors or officers.

Stakeholder Impact

• Shareholders may be impacted by the failure to meet the primary endpoint, potentially affecting the stock price and future prospects of ampreloxetine.
• Employees may face uncertainty due to the ongoing proposed transaction with Zymeworks Inc. and potential restructuring activities.

Next Steps

• Engage with the FDA on the design of a future clinical study for ampreloxetine.
• Potentially conduct an additional pivotal trial, subject to FDA feedback and further development.

Key Dates

Recommendation

The stock is held due to the significant setback of missing the primary endpoint in a Phase 3 trial. However, the company's continued engagement with the FDA and post hoc analysis suggesting potential benefit warrant a hold rather than an immediate sell, pending further clarity on the path forward for ampreloxetine.

Keywords

neurogenic orthostatic hypotension, ampreloxetine, CYPRESS Study, multiple system atrophy, clinical trial, FDA, drug development, Phase 3